Management

Franz Walt joined Quotient as the company’s Chief Executive Officer in May 2018. He previously led the company as its Interim CEO from March to May. Franz Walt has 30 years' experience in leadership roles at two of the largest, most influential healthcare companies, Siemens Healthineers and Roche, and serves as an expert advisor on the in-vitro diagnostics industry to manufacturing companies and private equity firms. His career has focused on business turnaround and market expansion, emphasizing innovation, strategic alliances, quality and commercialization. In December 2017 Mr. Walt retired as President of Siemens Healthineers, Laboratory Diagnostics, where he served as President since 2014. While at Roche, Mr. Walt served 8 years as a member of the Roche Diagnostics Executive Committee. His executive positions included CEO at Roche Diagnostics GmbH in Mannheim, Germany and positions of increasing responsibility in pharma and IVD. Mr. Walt served as a board member of the AdvaMed DX industry association, where he actively contributed to shape healthcare policy in diagnostic testing to improve patient health. Mr. Walt holds an M.B.A. from the City University of Bellevue (Washington).

Chris Lindop joined Quotient as our Chief Financial Officer in February 2017. He previously served as chief financial officer from January 2007 until June 2016 and as executive vice president of business development from August 2007 until May 2016 of Haemonetics Corporation (NYSE:HAE), a global leader in blood processing technology. From September 2003 to December 2006, he served as chief financial officer of Inverness Medical Innovations, Inc., a global developer, manufacturer and marketer of medical diagnostic products. From June 2002 to September 2003, he served as an audit partner with the Boston office of Ernst & Young LLP, an accounting firm. From 1991 to 2002, he served as an audit partner with the Boston office of Arthur Andersen LLP, an accounting firm. In addition, Mr. Lindop has served as a director of Parexel International Corporation (NASD: PRXL) since 2006, where he currently acts as chairman of the audit and finance committee and as a member of the nominating and governance committee. He holds a B.A. in Business from the University of Strathclyde (Scotland).

Jeremy has over 15 years in healthcare including diagnostics, pharmaceutical and biotechnology. His past experiences include former Commercial Director of Immunohematology, Ortho Clinical Diagnostics, Johnson & Johnson and former Strategy Consultant to healthcare industry with Monitor and McKinsey & Co consultancies.

Ed has 12 years diagnostics experience.  Previously he was VP of Manufacturing for Siemens Healthcare Diagnostics where he was the leader of a large reagent plant. Prior to that, he led a site manufacturing and developing point of care instruments and consumables for Siemens.  His past experiences include manufacturing, engineering, and logistics roles for Bayer Diagnostics, Ingersoll Rand and Intel. 

John has over 30 years experience in diagnostics and extensive knowledge of the global blood bank market. John spent 15  years working in Hospital & Transfusion Service Laboratories in the UK and Middle East, until moving into diagnostic reagent manufacturing in 1990. John was a Board Member at Scottish National Blood Transfusion Service from 1999 until 2007, Chairperson at EDMA Blood Typing Working Party from 1997 until 2007, a member of the EDMA representative to European Commission IVD Expert Group from 2001 until 2007, and a member of the UKBTS Reagents Standing Advisory Committee from 1994 until 2007.

Roland worked for over 20 years as an accounting professional with Andersen, latterly as a partner. Since 2002 he has worked in the healthcare sector initially as Group Financial Controller of Inveresk Research, a NASDAQ listed company and then for approximately six years from 2006 as Chief Financial Officer of Chiltern International, a leading global clinical research organisation. He joined Quotient in 2012 as Chief Financial Officer.